EXEL:NASDAQ
Exelixis Inc
$58.33
arrow_upward
+1.14%(+0.66) 1D
$58.33
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 9, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$57.60
High
$58.36
Low
$56.95
Mkt. cap
14.45B
Avg. vol.
2.53M
Volume
0.00
P/E ratio
18.32
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
Open
$57.60
High
$58.36
Low
$56.95
Mkt. cap
14.45B
Avg. vol.
2.53M
Volume
0.00
P/E ratio
18.32
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
Investing.com
·
15 hours ago
Exelixis at Citigroup summit: building a second growth engine
TipRanks
·
16 hours ago
Adagene Secures Milestone Payments in Exelixis SAFEbody ADC Collaboration
Stock Titan
·
17 hours ago
A cancer-drug milestone brings Adagene a $2 million payment
Investing.com
·
1 day ago
Exelixis at Wells Fargo conference: zanzalintinib takes center stage
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com